Latest Breaking News On - Squamous Cell

South African skin cancer patients undergo first treatments with OncoBeta s Rhenium-SCT as part of the EPIC-Skin study

South African skin cancer patients undergo first treatments with OncoBeta s Rhenium-SCT as part of the EPIC-Skin study
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesUnited kingdomSouth africaSouth africanGerhard dahlhoffOncobeta gmbMike sathekgeJane moreyPrnewswire oncobetaTherapeutic nuclear medicineInternational agency for research on cancerHead of nuclear medicine research infrastructure numeSteve biko academic hospitalSkin studyPersonalised irradiation

South African skin cancer patients undergo first treatments with OncoBeta s Rhenium-SCT as part of the EPIC-Skin study

South African skin cancer patients undergo first treatments with OncoBeta s Rhenium-SCT as part of the EPIC-Skin study
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesUnited kingdomSouth africaSouth africanGerhard dahlhoffOncobeta gmbMike sathekgeJane moreyPrnewswire oncobetaTherapeutic nuclear medicineInternational agency for research on cancerHead of nuclear medicine research infrastructure numeSteve biko academic hospitalSkin studyPersonalised irradiation

BioLineRx Announces Results from Phase 1/2a Study of Investigational Anti-Tumor Vaccine AGI-134 in Metastatic Solid Tumors

/PRNewswire/ BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, today announced results from.

United statesUnited kingdomMoran meirJohn laceyPhilip serlinPrnewswire biolinerx ltdLifesci advisorsExchange commission onBiolinerx ltdAgalimmune ltdStudy met primary endpointSeek publicationComplete data analysisChief executive officerTumor cancer typeSquamous cell

BioLineRx (BLRX) Report Results from Phase 1/2a Study of AGI-134

BioLineRx (BLRX) Report Results from Phase 1/2a Study of AGI-134
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomPhilip serlinBiolinerx ltdChief executive officerTumor cancer typeSquamous cellCervical node

Nivolumab Promising for Treatment of Advanced Cutaneous SCC

First-line nivolumab demonstrated antitumor activity and tolerability in a phase 2 trial of patients with aCSCC.

Rodrigor munhozBristol myers squibbHealthday newsSquamous cell

Latest Breaking News On - Squamous cell - Page 5 : comparemela.com

South African skin cancer patients undergo first treatments with OncoBeta s Rhenium-SCT as part of the EPIC-Skin study

South African skin cancer patients undergo first treatments with OncoBeta s Rhenium-SCT as part of the EPIC-Skin study

BioLineRx Announces Results from Phase 1/2a Study of Investigational Anti-Tumor Vaccine AGI-134 in Metastatic Solid Tumors

BioLineRx (BLRX) Report Results from Phase 1/2a Study of AGI-134

Nivolumab Promising for Treatment of Advanced Cutaneous SCC

First-line nivolumab demonstrated antitumor activity and tolerability in a phase 2 trial of patients with aCSCC.Rodrigor munhozBristol myers squibbHealthday newsSquamous cell

First-line nivolumab demonstrated antitumor activity and tolerability in a phase 2 trial of patients with aCSCC.

Rodrigor munhozBristol myers squibbHealthday newsSquamous cell